Atogepant is an oral calcitonin gene-related peptide (CGRP) receptor antagonist and is currently under clini- cal investigation for preventive treatment of migraine. Its inhibitory activity on vasodilatory response has been well demonstrated in vitro. Although pharmacokinetic and metabolism data are still not available, a recently completed phase II clinical trial reported a satisfactory safety and tolerability profile over a 12-week treatment period with doses ranging from 10 to 120 mg daily, with no occurring drug-related serious adverse events. Several other phase III open-label and placebo-controlled clinical trials are ongoing to evaluate atogepant safety in long- term administration. Atogepant showed a significant and clinically relevant efficacy in the decrease in migraine days compared to placebo. Drug–drug interactions po- tentially affecting atogepant pharmacokinetics should be assessed in future clinical trials.

Atogepant. Calcitonin gene-related peptide (CGRP) receptor antagonist, Preventive treatment of migraine / Martelletti, P.; Cipolla, F.; Capi, M.; Curto, M.; Lionetto, L.. - In: DRUGS OF THE FUTURE. - ISSN 0377-8282. - 45:5(2020), p. 285. [10.1358/dof.2020.45.5.3123467]

Atogepant. Calcitonin gene-related peptide (CGRP) receptor antagonist, Preventive treatment of migraine

Martelletti, P.
Primo
;
Cipolla, F.;Capi, M.;Curto, M.
Penultimo
;
2020

Abstract

Atogepant is an oral calcitonin gene-related peptide (CGRP) receptor antagonist and is currently under clini- cal investigation for preventive treatment of migraine. Its inhibitory activity on vasodilatory response has been well demonstrated in vitro. Although pharmacokinetic and metabolism data are still not available, a recently completed phase II clinical trial reported a satisfactory safety and tolerability profile over a 12-week treatment period with doses ranging from 10 to 120 mg daily, with no occurring drug-related serious adverse events. Several other phase III open-label and placebo-controlled clinical trials are ongoing to evaluate atogepant safety in long- term administration. Atogepant showed a significant and clinically relevant efficacy in the decrease in migraine days compared to placebo. Drug–drug interactions po- tentially affecting atogepant pharmacokinetics should be assessed in future clinical trials.
2020
Atogepant, AGN-241689, MK-8031, migraine, Calcitonin gene-related peptide, CGRP, receptor antagonist
01 Pubblicazione su rivista::01a Articolo in rivista
Atogepant. Calcitonin gene-related peptide (CGRP) receptor antagonist, Preventive treatment of migraine / Martelletti, P.; Cipolla, F.; Capi, M.; Curto, M.; Lionetto, L.. - In: DRUGS OF THE FUTURE. - ISSN 0377-8282. - 45:5(2020), p. 285. [10.1358/dof.2020.45.5.3123467]
File allegati a questo prodotto
File Dimensione Formato  
Martelletti_Atogepant_2020.pdf

solo gestori archivio

Note: https://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=3123467&p_IsPs=N
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 287.33 kB
Formato Adobe PDF
287.33 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1532167
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 14
social impact